Current Report Filing (8-k)
May 13 2020 - 7:08AM
Edgar (US Regulatory)
0000025743
false
0000025743
2020-05-13
2020-05-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE
ACT OF 1934
Date of Report
(Date of earliest event reported): May 13, 2020
(Exact Name of Registrant as Specified in its
Charter)
Nevada
|
|
001-00100
|
|
87-0233535
|
(State or Other
Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
951 Yamato Road, Suite 220
Boca Raton, FL 33431
|
(Address of Principal Executive Office) (Zip Code)
|
Registrant’s telephone number, including area code: (561) 961-1900
Not Applicable
|
(Former name or former address, if changed since last report)
|
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
|
Trading Symbol
|
Name of Each Exchange on Which Registered
|
Common Stock, par value $0.001 per share
|
TXMD
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230-405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if
the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01
|
Regulation FD Disclosure.
|
TherapeuticsMD, Inc. is
furnishing as Exhibit 99.1 to this Current Report on Form 8-K an investor presentation which will be used, in whole or in part,
and subject to modification, on May 13, 2020 and at subsequent meetings with investors or analysts.
The information in this
Current Report on Form 8-K (including the exhibit) is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed
to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that section, nor will any of such information or exhibits be deemed incorporated by reference into any filing
under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth
by specific reference in such filing.
Item 9.01
|
Financial Statements and Exhibits.
|
Exhibit Index
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: May 13, 2020
|
THERAPEUTICSMD, INC.
|
|
|
|
|
|
By:
|
/s/ Daniel A. Cartwright
|
|
Name:
|
Daniel A. Cartwright
|
|
Title:
|
Chief Financial Officer
|
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From Sep 2023 to Sep 2024